Effects of Melatonin in Two Individuals with Alzheimer's Disease

Jean-Louis, Girardin; Zizi, Ferdinand; Gizycki, Hans von; Taub, Harvey B.

doi:10.2466/pms.1998.87.1.331

Cited by 30 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis revealed a significant decrease in agitated behavior and a significant decrease in daytime sleepiness. In a case report observation on two AD patients, melatonin administration enhanced and stabilized the circadian rest-activity rhythm in one of them along with reduction of daytime sleepiness and improvement in mood (Jean-Louis et al, 1998b). Likewise, another observation on two AD patients given 6 mg melatonin daily for one year indicated appreciable improvement of the Mini-Mental score (Pappolla et al, 2000).…”

Section: Clinical Application: Melatonin Sleep and Alzheimer's Diseasementioning

confidence: 97%

The Use of Melatonin as a Chronobiotic-Cytoprotective Agent in Sleep Disorders

Cardinali¹

2005

The Physiologic Nature of Sleep

View full text Add to dashboard Cite

Section: Clinical Application: Melatonin Sleep and Alzheimer's Diseasementioning

confidence: 97%

The Use of Melatonin as a Chronobiotic-Cytoprotective Agent in Sleep Disorders

Cardinali¹

2005

The Physiologic Nature of Sleep

View full text Add to dashboard Cite

“…Based on the aforementioned relationship between AD and melatonin, the effectiveness of melatonin substitution therapy has been demonstrated in treating sleep disorder associated with CRSD in AD [42,43]. Asayama et al reported that treatment with melatonin significantly prolonged sleep duration and decreased nighttime activity in AD patients, compared to placebo.…”

Section: Therapy Of Sleep Disorders In Ad Patientsmentioning

confidence: 99%

Circadian Rhythm Sleep Disorder in Alzheimer’s Disease-A consideration in relation with the Neuropathological and Neuroendocrinal alternation

Umetsu¹,

Fukumoto

Sakurai³

et al. 2014

Brain Disord Ther

View full text Add to dashboard Cite

The Circadian rhythm sleep disorder of the dementia is apt to cause night wandering, delirium and even sundowning syndrome. And these behaviors put a major burden on the patients themselves and their caregivers. The ratio of complication of Circadian rhythm sleep disorder in Alzheimer's disease, the major figure of dementia, is considerably high. Circadian rhythm sleep disorder in Alzheimer's disease is supposed to be caused by physiological change of the internal secretion rhythm, physical disorder and/or environmental factors. Furthermore, in recent years, in addition to the high rate of coexistence, it has been reported that there may be essential relation between circadian rhythm sleep disorder and Alzheimer's disease. In the present study, we summarized the role of neuropathological and neuroendocrinal alternation in Circadian rhythm sleep disorder of Alzheimer's disease.

show abstract

“…63 La administración de esta indolamina a sujetos que padecen EA causa una mejoría en los trastornos de los ritmos circadianos [64][65][66] así como una reducción en la disfunción cognitiva. 67 Los estudios preclínicos apoyan este concepto ya que la MEL actúa como un captador de radicales libres y por lo tanto reduce el estrés oxidativo y la apoptosis.…”

Section: La Melatonina Como Una Alternativa En El Tratamiento De Las unclassified

La melatonina como un factor promotor de la diferenciación neuronal: implicaciones en el tratamiento de las demencias

et al. 2013

View full text Add to dashboard Cite

SUMMARYDementias are progressive and neurodegenerative neuropsychiatric disorders, with a high worldwide prevalence. These disorders affect memory and behavior, causing impairment in the performance of daily activities and general disability in the elders. Cognitive impairment in these patients is related to anatomical and structural alterations at cellular and sub-cellular levels in the Central Nervous System. In particular, amyloid plaques and neurofibrillar tangles have been defined as histopathological hallmarks of Alzheimer's disease. Likewise, oxidative stress and neuroinflammation are implicated in the etiology and progression of the disease.Neuronal precursors from human olfactory neuroepithelium have been recently characterized as an experimental model to identify neuropsychiatric disease biomarkers. Moreover, this model not only allows the study of neuropsychiatric physiopathology, but also the process of neurodevelopment at cellular, molecular and pharmacological levels.This review gathers the evidence to support the potential therapeutic use of melatonin for dementias, based on its antioxidant properties, its anti-inflammatory effect in the brain, and its ability to inhibit both tau hyper-phosphorylation and amyloid plaque formation. Furthermore, since melatonin stimulates neurogenesis, and promotes neuronal differentiation by inducing the early stages of neuritogenesis and dendrite formation, it has been suggested that melatonin could be useful to counteract the cognitive impairment in dementia patients.Key words: Melatonin, dementia, biomarkers, neuroepithelium, neuritogenesis. RESUMENLas demencias son enfermedades neuropsiquiátricas, progresivas, neurodegenerativas y con una alta prevalencia a nivel mundial. Ocupan uno de los primeros lugares como enfermedades que causan incapacidad en los adultos mayores. En estos pacientes el Sistema Nervioso Central presenta alteraciones anatómico-estructurales a nivel celular y subcelular que se asocian con deficiencias cognitivas. En particular, en la enfermedad de Alzheimer se han caracterizado marcadores histopatológicos como las placas amiloides y las marañas neurofibrilares. Se sabe que el estrés oxidativo y la neuroinflamación participan en la etiología y el desarrollo de la enfermedad. Recientemente se caracterizó a los precursores neuronales del neuroepitelio olfatorio humano como un modelo experimental adecuado para identificar biomarcadores de rasgo y para estudiar la fisiopatología de diversas enfermedades neuropsiquiátricas, así como el proceso del neurodesarrollo, a nivel celular, molecular y farmacológico. En este trabajo se presenta la evidencia que sustenta que la melatonina puede ser útil en el tratamiento de las demencias, por su capacidad antioxidante, por su efecto anti-inflamatorio, así como por el efecto inhibidor de la hiperfosforilación de la proteina tau y de la formación de placas amiloides. Además, al estimular la formación de nuevas neuronas, la neuritogénesis en sus etapas tempranas y la formación de dendritas, la melatonina podría...

show abstract

Effects of Melatonin in Two Individuals with Alzheimer's Disease

Cited by 30 publications

References 20 publications

The Use of Melatonin as a Chronobiotic-Cytoprotective Agent in Sleep Disorders

The Use of Melatonin as a Chronobiotic-Cytoprotective Agent in Sleep Disorders

Circadian Rhythm Sleep Disorder in Alzheimer’s Disease-A consideration in relation with the Neuropathological and Neuroendocrinal alternation

La melatonina como un factor promotor de la diferenciación neuronal: implicaciones en el tratamiento de las demencias

Contact Info

Product

Resources

About